DETAILED ACTION
Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
Status of the Claims
Claims 1 and 2-22 are pending in the instant application and subject to examination herein.
Information Disclosure Statement
The information disclosure statements (IDS) submitted on 07/31/2026 are in compliance with the provisions of 37 CFR 1.97. Accordingly, the information disclosure statements are being considered by the examiner.
Claim Rejections – Withdrawn
The prior rejection of claim 1 under 35 U.S.C. 102(a)(1) as being anticipated by Vishnudas (U.S. Patent No. 11,091,447 B2) has been overcome by Applicant’s amendment of claim 1 has been overcome by Applicant’s amendment of claim 1, and is accordingly withdrawn. Specifically, Applicant’s amendment of claim 1 to further limit the scope of cancers to be treated in the claimed method to cancers that are not disclosed as treatable by Vishnudas has overcome the prior rejection.
The prior provisional rejection of claim 1 on the ground of nonstatutory double patenting as being unpatentable over claim 1 of copending Application No. 18/711,570 has been overcome by Applicant’s amendment of claim 1, and is accordingly withdrawn. Specifically, Applicant’s amendment of claim 1 to further limit the scope of cancers to be treated in the claimed method to a Markush group that does not include gastric cancer has overcome the prior rejection.
Claim Rejections - 35 USC § 102 – Maintained
The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:
A person shall be entitled to a patent unless –
(a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention.
(a)(2) the claimed invention was described in a patent issued under section 151, or in an application for patent published or deemed published under section 122(b), in which the patent or application, as the case may be, names another inventor and was effectively filed before the effective filing date of the claimed invention.
The prior rejection of claim 10 under 35 U.S.C. 102(a)(1) as being anticipated by Vishnudas (U.S. Patent No. 11,091,447 B2) is maintained. Applicant has traversed the prior rejection on the grounds that Vishnudas does not disclose that breast cancer is a P-gp-mediated resistant cancer; however, the property of being a P-gp-mediated resistant cancer is an inherent property of breast cancer, and would have been recognizable to a person of ordinary skill in the art, as this was known in the art in advance of the effective filing date of the instant application. See, for example, Clark (Clarke, R., et al.; Seminars in Oncology, v32, Supplement 7, ppS9-S15; 2005). Clark teaches that exposure of previously untreated breast cancer to anticancer drugs is often followed by acquisition of multidrug resistance, and that one of the more widely studied mechanisms of drug resistance is the function of P-glycoprotein (P-gp), a membrane transporter with a wide range of substrates, including several anticancer agents, and a member of the ATP-binding cassette superfamily of proteins, and that P-gp expression is detected in a significant percentage of breast cancers (Abstract). Thus, the attribute of being a P-gp mediated resistant cancer is an inherent attribute of breast cancer, and was known well in advance of the effective filing date of the instant application.
Claim 10 is anticipated by Vishnudas.
Claim 10 is rejected under 35 U.S.C. 102(a)(1) as being anticipated by Vishnudas (U.S. Patent No. 11,091,447 B2).
Claim 10 is drawn to a method of treating a P-gp-mediated resistant cancer comprising administering to a subject in need thereof, a therapeutically effective amount of 2-(difluoromethoxy)-N-[[5-(2-methoxyphenyl)-1H-1,2,4-triazol-3-yl]methyl]benzamide, or a pharmaceutically acceptable salt thereof.
Vishnudas discloses methods of treating cancers, comprising administering a therapeutically effective amount of a compound disclosed therein to a subject in need thereof, including breast cancer (Col. 8, lines 8-35), and discloses the compound 2-(difluoromethoxy)-N-[[5-(2-methoxyphenyl)-1H-1,2,4-triazol-3-yl]methyl]benzamide as compound “32” (Col. 65, Table 7; and Col. 83, lines 1-18). Vishnudas does not disclose that breast cancer is a cancer that is a P-gp-mediated resistant cancer; however, a person of ordinary skill in the art would at once recognize that breast cancer is a P-gp-mediated resistant cancer, as this is an inherent property of breast cancer that is known in the art – see, for example, Clark (Clarke, R., et al.; Seminars in Oncology, v32, Supplement 7, ppS9-S15; 2005), who teaches a review on multidrug resistance in regard to P-Glycoprotein and breast cancer. Clark teaches that exposure of previously untreated breast cancer to anticancer drugs is often followed by acquisition of multidrug resistance, and that one of the more widely studied mechanisms of drug resistance is the function of P-glycoprotein (P-gp), a membrane transporter with a wide range of substrates, including several anticancer agents, and a member of the ATP-binding cassette superfamily of proteins, and that P-gp expression is detected in a significant percentage of breast cancers (Abstract).
Thus, claim 10 is anticipated by the disclosure of Vishnudas.
Double Patenting – Maintained
The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).
A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b).
The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13.
The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer.
The prior rejection of claims 1 and 3-22 on the ground of nonstatutory double patenting as being unpatentable over claims 1-2, 5-6 and 8 of U.S. Patent No. 11,091,447 B2 (hereafter referred to as “Vishnudas”) is maintained. Applicant has attested, within the Remarks letter dated 07/31/2026, to the submission of a Terminal Disclaimer over Vishnudas. However, no such Terminal Disclaimer is found on file for the instant application.
Reiterated Rejection:
Claims 1 and 3-22 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-2, 5-6 and 8 of U.S. Patent No. 11,091,447 B2 (hereafter referred to as “Vishnudas”). Although the claims at issue are not identical, they are not patentably distinct from each other because the claims of Vishnudas claim the same compound1 (or pharmaceutically acceptable salt thereof) that is required for the method(s) claimed in each/all of the instant claims.
Conclusion
THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).
A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.
Any inquiry concerning this communication or earlier communications from the examiner should be directed to W. JUSTIN YOUNGBLOOD whose telephone number is (703)756-5979. The examiner can normally be reached on Monday-Thursday from 8am to 5pm. The examiner can also be reached on alternate Fridays.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Jeffrey S. Lundgren, can be reached at telephone number (571) 272-5541. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of an application may be obtained from Patent Center. Status information for published applications may be obtained from Patent Center. Status information for unpublished applications is available through Patent Center to authorized users only. Should you have questions about access to the USPTO patent electronic filing system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).
Examiner interviews are available via a variety of formats. See MPEP § 713.01. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) Form at https://www.uspto.gov/InterviewPractice.
/W.J.Y./Examiner, Art Unit 1629
/JEFFREY S LUNDGREN/Supervisory Patent Examiner, Art Unit 1629
1 2-(difluoromethoxy)-N-[[5-(2-methoxyphenyl)-1H-1,2,4-triazol-3-yl]methyl]benzamide